Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 50,362 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Empathic Communication Skills (ECS) Training

NCT05456841
View directory record Official record
Conditions
Lung Cancer
Interventions
Empathic Communication Skills (ECS) training, Standard of Care participant interaction
Behavioral · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 100 Years
Enrollment
1,232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
12
States / cities
Irvine, California • Miami, Florida • Libertyville, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors

NCT01927341
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
MEK162, Panitumumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 31, 2026, 5:15 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma

NCT00378105
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, Lenalidomide, dexamethasone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 31, 2026, 5:15 PM EDT
Terminated Not applicable Interventional Results available

Electromagnetic Tracking and Optical Imaging With ICG for Hepatic Biopsies

NCT04258566
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Optical Molecular Imaging (OMI), Indocyanine Green (ICG), Electromagnetic Tracking
Device · Radiation
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 31, 2026, 5:15 PM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab in Treating Patients With Advanced Uveal Melanoma

NCT02359851
View directory record Official record
Conditions
Stage IIIA Uveal Melanoma, Stage IIIB Uveal Melanoma, Stage IIIC Uveal Melanoma, Stage IV Uveal Melanoma
Interventions
Pembrolizumab, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Chicago, Illinois • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 1 Interventional

Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant

NCT00434629
View directory record Official record
Conditions
B-cell Lymphoma, Non-Hodgkin's Lymphoma
Interventions
Bexxar
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Not applicable Interventional

A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients

NCT05909202
View directory record Official record
Conditions
Neoplasm, Caregivers
Interventions
Sham VR, Active VR
Device
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 100 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 31, 2026, 5:15 PM EDT
Active, not recruiting Phase 3 Interventional

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

NCT03803553
View directory record Official record
Conditions
Metastatic Colon Cancer, Stage III Colon Cancer
Interventions
FOLFIRI Protocol, ACTIVE SURVEILLANCE, Nivolumab Protocol, Encorafenib/Binimetinib/Cetuximab Protocol, Trastuzumab + Pertuzumab
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 31, 2026, 5:15 PM EDT
Recruiting Not applicable Interventional

Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer

NCT06543537
View directory record Official record
Conditions
Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma
Interventions
Collaborative Agenda-Setting Intervention
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 1 Interventional

Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic Leukemia

NCT00004245
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
sodium salicylate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 31, 2026, 5:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer

NCT01591772
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
Interventions
Neuroimaging & Neuropsychological Evaluation
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 70 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Oct 31, 2026, 5:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Biology of Osteosarcoma (BOOST) Registry and Biobank

NCT03225872
View directory record Official record
Conditions
Osteosarcoma
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
0 Years and older
Enrollment
362 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 31, 2026, 5:15 PM EDT
Recruiting Early Phase 1 Interventional

Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma

NCT07076472
View directory record Official record
Conditions
Progressive Glioblastoma, Recurrent Glioblastoma
Interventions
Aminolevulinic Acid Intravenous Formulation SONALA-001, Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Magnetic Resonance Imaging, MRI-Guided Focused Ultrasound Ablation, Oral Aminolevulinic Acid Hydrochloride
Drug · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 1 Interventional

Study of Nesvacumab (REGN910/ SAR307746)

NCT01271972
View directory record Official record
Conditions
Solid Tumors
Interventions
nesvacumab (REGN910/ SAR307746)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
San Francisco, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2015 · Synced Oct 31, 2026, 5:15 PM EDT
Withdrawn Phase 2 Interventional

Prospective Evaluation of a New Covered Metal Stent for Malignant Lesions of the Esophagus

NCT01301495
View directory record Official record
Conditions
Esophageal Cancer
Interventions
HANAROSTENT TM covered Esophageal Stent
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 31, 2026, 5:15 PM EDT
Completed No phase listed Observational

Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab

NCT07091695
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab + relatlimab, Nivolumab + ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Dublin, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 1Phase 2 Interventional

Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate

NCT00093639
View directory record Official record
Conditions
Leukemia
Interventions
everolimus, imatinib mesylate
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 31, 2026, 5:15 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies

NCT02623439
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 31, 2026, 5:15 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.

NCT07389239
View directory record Official record
Conditions
Ovarian Cancer, Advanced Malignant Solid Tumor
Interventions
Decitabine, Cyclophosphamide Conditioning, NY-ESO-1 TCR/ dnTGFβRII, Aldesleukin
Drug · Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 2 Interventional

Treatment With SU11248 in Patients With Neuroendocrine Tumors

NCT00056693
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
Sunitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2008 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 2 Interventional Results available

1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation

NCT03133221
View directory record Official record
Conditions
Non Hodgkin Lymphoma, Follicular Lymphoma, Indolent Lymphoma, B-cell Lymphoma, Transformed Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma
Interventions
Zydelig
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Miami, Florida • Baltimore, Maryland • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 31, 2026, 5:15 PM EDT
Recruiting Phase 2 Interventional

Hypofractionated Radiotherapy With a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer

NCT07325721
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy
Interventions
Hypofractionated radiation with a microboost
Radiation
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 31, 2026, 5:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer

NCT00482014
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer
Interventions
pemetrexed, cisplatin, carboplatin, radiation therapy
Drug · Radiation
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
9
States / cities
Los Angeles, California • Wichita, Kansas • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2012 · Synced Oct 31, 2026, 5:15 PM EDT
Terminated Phase 2 Interventional

Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes

NCT00104806
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
cholecalciferol, arsenic trioxide
Dietary Supplement · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 120 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Oct 31, 2026, 5:15 PM EDT